Corcept Therapeutics Incorporated - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CORT Nasdaq 2830 www.corcept.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Corcept Therapeutics Incorporated

Medical Stock Soars To Highs As Cortisol Screening Grows - Jan 22nd, 2025 4:35 pm
Here’s Why Analysts Are Bullish on Corcept Therapeutics Incorporated (CORT) - Jan 20th, 2025 11:53 pm
Corcept Therapeutics Incorporated (CORT): Why Should You Buy This Growth Stock For The Next 5 Years? - Jan 18th, 2025 6:59 pm
Discover 3 US Growth Stocks With Strong Insider Ownership - Jan 7th, 2025 3:06 pm
Corcept Therapeutics Incorporated (CORT) Surged on Strong Results and Increased Guidance - Jan 7th, 2025 1:04 pm
Corcept Submits Application for Another Cushing's Syndrome Drug - Dec 31st, 2024 6:40 pm
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism - Dec 30th, 2024 10:15 pm
Will Corcept Therapeutics Incorporated (CORT) Make You Rich In 2025? - Dec 25th, 2024 4:13 am
Corcept Therapeutics’ Cushing’s syndrome therapy shows promise in Phase III trial - Dec 17th, 2024 10:16 am
Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism - Dec 16th, 2024 1:00 pm
Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes - Dec 13th, 2024 1:53 pm
Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes - Dec 12th, 2024 9:05 pm
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study - Dec 12th, 2024 3:21 pm
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) - Dec 11th, 2024 9:05 pm
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating - Dec 11th, 2024 8:06 pm
Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock - Dec 11th, 2024 2:50 pm
Corcept (CORT) is an Incredible Growth Stock: 3 Reasons Why - Dec 9th, 2024 5:45 pm
Ionis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound? - Dec 6th, 2024 4:31 pm
Wall Street Analysts See a 26.05% Upside in Corcept (CORT): Can the Stock Really Move This High? - Dec 6th, 2024 2:55 pm
3 US Stocks With High Insider Ownership And Up To 79% Growth - Dec 5th, 2024 11:05 am